News | March 07, 2026
Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial
The company announced positive topline data from the Phase II ZUPREME-1 trial
The company announced positive topline data from the Phase II ZUPREME-1 trial
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Merck emphasized the broader significance of the findings
This study evaluated a difficult-to-treat Crohn's disease patient population
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
If approved, DTX401 would be the first treatment to address the disease at its root cause
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Subscribe To Our Newsletter & Stay Updated
